查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1929523

抗澱粉樣蛋白藥物市場按藥物類型、適應症、給藥途徑、患者階段、最終用戶和分銷管道分類，全球預測（2026-2032年）

Anti-amyloid Drugs Market by Drug Type, Indication, Route Of Administration, Patient Stage, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗澱粉樣蛋白藥物市場價值將達到 52.5 億美元，到 2026 年將成長至 56.8 億美元，年複合成長率為 7.21%，到 2032 年將達到 85.5 億美元。

關鍵市場統計數據
基準年 2025 52.5億美元
預計年份：2026年 56.8億美元
預測年份 2032 85.5億美元
複合年成長率 (%) 7.21%

本文簡要概述了當前抗澱粉樣蛋白治療領域，重點介紹了臨床進展、關鍵營運挑戰和策略決策點。

全球對有效抗澱粉樣蛋白療法的探索是近幾十年來神經退化性疾病治療領域最重要的轉捩點之一。近期臨床進展已將靶向澱粉樣蛋白的療法從實驗概念提升為切實可行的治療策略，重新激發了臨床、監管、支付者和投資者的關注。因此，相關人員正在重新評估臨床路徑、投資重點和製造地，以適應新的治療策略、不斷變化的安全性考量和日益複雜的診斷方法。

科學突破、診斷技術進步以及不斷變化的監管和支付框架如何重塑臨床開發和商業化策略

抗澱粉樣蛋白領域的變化正在加速，涵蓋研究、臨床應用和生態系統準備等各個方面，這正在改變各機構規劃近期商業化和長期產品組合分配的方式。單株抗體工程技術的進步，結合更靈敏的診斷方法，使得早期檢測和介入策略成為可能。同時，監管機構正在調整其審查框架，以納入替代終點和新型風險效益評估，這迫使申辦方設計能夠整合認知結果和生物標記趨勢的試驗。

評估2025年美國關稅變化對抗澱粉樣蛋白療法的供應鏈、採購和定價策略的實際影響

美國將於2025年實施的新關稅為依賴跨境供應鏈和進口原料的製造商、經銷商和醫療保健系統帶來了巨大衝擊。關稅相關的成本轉嫁可能會擾亂已協商的供應商契約，並增加用於單株抗體和疫苗生產的生物製藥和特種試劑的到岸成本。這將要求採購部門重新評估籌資策略和庫存政策，以降低關稅波動帶來的風險，並維持輸液中心和專科藥房的持續供應。

基於深度細分的洞察，將治療方法、給藥途徑、患者階段和通路映射到商業性和臨床優勢。

細緻的細分框架闡明了治療藥物的研發路徑和商業管道，突顯了臨床、生產和市場准入挑戰的交匯點。根據藥物類型，該框架涵蓋單株抗體、胜肽療法、小分子抑制劑和疫苗。在單株抗體中，產品可分為嵌合體、全人源型、人源化型和鼠源型；小分子抑制劑可分為聚集抑制劑和分泌酶抑制劑；疫苗則分為DNA疫苗和胜肽疫苗。這些差異具有重要的臨床和營運意義，因為分子形式會影響免疫抗原性風險、給藥頻率、生產複雜性和低溫運輸要求，進而影響研發週期和生產資本投入。

美洲、歐洲、中東和非洲以及亞太地區的區域策略趨勢將影響臨床專案、監管策略和市場進入途徑。

區域趨勢將對美洲、歐洲、中東和非洲以及亞太市場的臨床試驗進行、監管互動、生產決策和報銷談判產生不同的影響。在美洲，監管先例和大規模綜合醫療保健系統創造了一個環境，​​使得支付方的參與和真實世界證據的產生能夠迅速影響藥物的採納和醫保覆蓋決策。同時，該地區強大的臨床試驗網路支持快速招募患者以拓展適應症並進行核准後研究，但這需要對輸注能力和分散式試驗環節進行周密規劃。

領先的生物製藥公司在抗澱粉樣蛋白領域塑造其競爭地位的策略（產品線多元化、夥伴關係、生產規模化、診斷整合）

為了在抗澱粉樣蛋白領域保持競爭優勢，領先的生物製藥公司正在整合藥物發現、臨床開發和生產方面的能力。多家贊助商正致力於多元化的產品線，包括具有最佳化Fc工程的新一代單株抗體、靶向聚集途徑的小分子藥物以及旨在產生持久免疫反應的疫苗平台。策略夥伴關係和授權協議正在加速生產能力的規模化，使企業能夠快速獲得專業製劑技術，並促進共用監管和商業風險的合作開發模式。

為企業提供具體、實用的建議，以最佳化診斷、生產彈性、即時檢測策略和支付方參與度，從而最大限度地提高產品上市和市場准入。

產業領導者應優先採取簡單易行的措施，使臨床目標與商業性和營運實際情況相符。首先，與生物標記提供者和支付方建立合作關係，整合診斷和治療路徑，從而實現更早的患者識別和治療結果追蹤。這有助於減少患者就醫過程中的摩擦，並基於真實世界數據增強醫保覆蓋的合理性。其次，透過擴大地理分散的生產能力，並實施模組化填充和包裝解決方案，投資於靈活的生產製造和供應鏈冗餘，以應對關稅和物流中斷的影響。

我們採用透明、穩健的調查方法，結合專家訪談、監管和臨床證據整合以及情境驅動的分析技術，為策略決策提供支援。

本分析整合了第一手和第二手調查方法，旨在對澱粉樣蛋白治療生態系統進行嚴謹而全面的剖析。第一手研究包括對臨床專家、支付方和生產企業負責人進行結構化訪談，以及諮詢監管事務專家和診斷服務提供商，以驗證假設的準確性。這些定性研究結果與公開的監管文件、同行評審文獻、臨床試驗註冊資訊和公司披露資訊進行三角驗證，以檢驗臨床結果、安全性訊號和策略定位。

將臨床進展、營運要務和策略重點整合起來，領導者必須解決這些問題，才能將科學進步轉化為持續的病患可及性和商業性成功。

總之，抗澱粉樣蛋白治療領域兼具科學進步與系統複雜性，需要整合且積極主動的策略。儘管臨床進展已創造出可靠的治療方案，但其商業性成功將取決於對診斷技術、生產靈活性、支付方合作以及以患者為中心的供應模式的協調投資。包括關稅調整和不斷變化的報銷模式在內的政策趨勢，進一步凸顯了供應鏈多元化和合約柔軟性的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類型分類的抗澱粉樣蛋白藥物市場

  • 單株抗體
    • 嵌合體體
    • 完全人類
    • 人性化
    • 小鼠衍生
  • 基於胜肽的療法
  • 小分子抑制劑
    • 凝血抑制劑
    • 分泌酶抑制劑
  • 疫苗
    • DNA疫苗
    • 胜肽疫苗

9. 依適應症分類的抗澱粉樣蛋白藥物市場

  • 阿茲海默症
  • 亨丁頓舞蹈症
  • 多發性硬化症
  • 帕金森氏症

第10章 依給藥途徑分類的抗澱粉樣蛋白藥物市場

  • 鞘內給藥
  • 靜脈注射
    • 住院患者的靜脈注射滴注
    • 門診輸液
  • 口服
    • 膠囊
    • 液體
    • 藥片
  • 皮下注射

第11章：依患者階段分類的抗澱粉樣蛋白藥物市場

  • 早期
  • 後期
  • 中期

第12章 依最終用戶分類的抗澱粉樣蛋白藥物市場

  • 居家醫療環境
  • 醫院
  • 專科診所

第13章 抗澱粉樣蛋白藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 各地區抗澱粉樣蛋白藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 抗澱粉樣蛋白藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國抗澱粉樣蛋白藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國抗澱粉樣蛋白藥物市場

第18章：中國的抗澱粉樣蛋白藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
Product Code: MRR-0A38069517F3

The Anti-amyloid Drugs Market was valued at USD 5.25 billion in 2025 and is projected to grow to USD 5.68 billion in 2026, with a CAGR of 7.21%, reaching USD 8.55 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.25 billion
Estimated Year [2026] USD 5.68 billion
Forecast Year [2032] USD 8.55 billion
CAGR (%) 7.21%

A concise framing of the contemporary anti-amyloid therapeutics landscape that highlights clinical momentum, operational imperatives, and strategic decision points

The global pursuit of effective anti-amyloid therapies marks one of the most consequential shifts in neurodegenerative disease management in recent decades. Recent clinical advances have elevated amyloid-targeting approaches from experimental concepts to actionable therapeutic strategies, prompting renewed interest across clinical, regulatory, payer, and investor communities. As a result, stakeholders are reassessing clinical pathways, investment priorities, and manufacturing footprints to adapt to emerging therapeutic profiles, evolving safety considerations, and refined diagnostic paradigms.

This executive summary synthesizes critical insights across clinical innovation, regulatory dynamics, supply chain resilience, and commercial strategy. It contextualizes therapeutic modalities, routes of administration, patient segmentation, and end-user channels to provide a cohesive picture of near-term operational implications. Furthermore, it highlights strategic inflection points that organizations must address to translate scientific advances into sustainable patient access and organizational value. In doing so, the summary equips leaders with the evidence-based perspective needed to prioritize initiatives, allocate resources effectively, and anticipate cross-functional risks and opportunities.

How converging scientific breakthroughs, diagnostic advances, and evolving regulatory and payer frameworks are reshaping clinical development and commercialization strategies

Transformative shifts in the anti-amyloid landscape have accelerated across research, clinical deployment, and ecosystem readiness, altering how organizations plan for near-term commercialization and long-term portfolio allocation. Advances in monoclonal antibody engineering, coupled with more sensitive diagnostic modalities, have enabled earlier detection and intervention strategies. Concurrently, regulatory agencies have adapted review frameworks to account for surrogate endpoints and novel benefit-risk assessments, prompting sponsors to design trials that integrate cognitive outcomes with biomarker trajectories.

Operationally, payers and health systems are piloting outcomes-based reimbursement constructs and coverage-with-evidence arrangements to balance access with budgetary stewardship. Manufacturing models are evolving to support intermittent infusion and subcutaneous delivery, while diagnostics providers scale capacity for amyloid PET imaging and fluid biomarkers. Taken together, these shifts compel integrated planning across R&D, medical affairs, market access, and manufacturing to ensure coherent product launches, equitable patient identification, and sustainable reimbursement pathways.

Assessing the practical consequences of the 2025 United States tariff changes on supply chains, procurement, and pricing strategies for anti-amyloid therapeutics

The imposition of new tariff measures in the United States in 2025 introduced a notable variable for manufacturers, distributors, and health systems that rely on cross-border supply chains and imported raw materials. Tariff-related cost pass-throughs can disrupt negotiated supplier contracts and increase the landed cost of biologics and specialized reagents used in monoclonal antibody and vaccine production. As a result, procurement functions must reassess sourcing strategies and inventory policies to mitigate exposure to variable duties and to maintain continuity of supply for infusion centers and specialty pharmacies.

Consequently, firms are evaluating alternative mitigation strategies including nearshoring critical manufacturing steps, diversifying supplier bases across tariff-exempt jurisdictions, and renegotiating long-term supply agreements to incorporate tariff contingency clauses. In parallel, manufacturers with vertically integrated capabilities can buffer impact by internalizing key steps such as cell-line production and fill-finish operations. For health systems and payers, the policy change emphasizes the need to reexamine unit cost assumptions, adjust budgetary forecasts, and consider contracting mechanisms that protect against episodic tariff shocks. Ultimately, tariff pressures amplify the strategic importance of supply chain resilience, contractual flexibility, and geographic diversification in the anti-amyloid therapeutic ecosystem.

Deep segmentation-driven insights that map therapeutic modalities, routes of administration, patient stages, and distribution pathways to commercial and clinical levers

A nuanced segmentation framework clarifies therapeutic development pathways and commercial channels and illuminates where clinical, manufacturing, and access challenges converge. Based on drug type, the landscape spans monoclonal antibodies, peptide-based therapies, small molecule inhibitors, and vaccines; within monoclonal antibodies, product differentiation includes chimeric, fully human, humanized, and murine formats, while small molecule inhibitors break down into aggregation inhibitors and secretase inhibitors, and vaccines separate into DNA vaccines and peptide vaccines. These distinctions matter clinically and operationally because molecule format influences immunogenicity risk, dosing frequency, production complexity, and cold-chain requirements, thereby shaping development timelines and manufacturing capital intensity.

Based on indication, clinical application extends beyond Alzheimer's disease to include Huntington's disease, multiple sclerosis, and Parkinson's disease, each presenting unique biomarker profiles and patient journey bottlenecks. Based on route of administration, therapies are administered intrathecally, intravenously, orally, or subcutaneously, with intravenous delivery further delineated into inpatient infusion and outpatient infusion settings and oral formulations categorized by capsule, liquid, and tablet presentations. These administration channels directly affect site-of-care economics, adherence dynamics, and patient preference patterns. Based on end user, delivery settings encompass home care environments, hospitals, and specialty clinics, which in turn determine training needs, nursing capacity, and reimbursement coding. Based on distribution channel, the flow of therapies moves through hospital pharmacies, online pharmacies, and retail pharmacies, each with distinct fulfillment requirements and regulatory considerations. Based on patient stage, segmentation across early stage, mid stage, and late stage cohorts informs clinical benefit expectation, treatment sequencing, and payer negotiation strategies.

Synthesizing these segmentation layers reveals where incremental investments will yield disproportionate returns: optimizing delivery formats for outpatient and home care; aligning diagnostic algorithms to indication-specific biomarker requirements; and tailoring distribution models to support adherence and cold-chain logistics. In short, a segmentation-aware strategy enables targeted development, efficient commercialization, and more effective patient access planning.

Regional strategic dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence clinical programs, regulatory strategy, and market access pathways

Regional dynamics shape clinical trial conduct, regulatory engagement, manufacturing decisions, and reimbursement negotiations in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, regulatory precedent-setting decisions and large integrated health systems create a landscape where payer engagement and real-world evidence generation can rapidly influence uptake and coverage determinations. Meanwhile, the region's robust clinical trial networks support accelerated enrollment for indication expansion and post-approval studies, but also demand careful planning for infusion capacity and decentralized trial elements.

In the Europe, Middle East & Africa region, heterogeneous regulatory frameworks and variable reimbursement systems require adaptive market access strategies, including early dialogue with national health authorities, localized health economic modeling, and flexible pricing arrangements. Moreover, the need to accommodate both advanced medical centers and resource-constrained settings influences distribution and patient support program design. Asia-Pacific presents a combination of fast-growing demand, expanding diagnostics infrastructure, and varied regulatory timelines; countries in this region often prioritize domestic manufacturing partnerships and technology transfer to build local capacity. Across all regions, strategic geographic alignment of manufacturing, clinical development, and commercialization resources can reduce lead times, support regulatory filings, and enhance resilience against policy and supply-chain shocks.

How leading biopharma strategies-spanning pipeline diversification, partnerships, manufacturing scale-up, and diagnostic integration-are shaping competitive positioning in the anti-amyloid field

Leading biopharmaceutical organizations are consolidating capabilities across discovery, clinical development, and manufacturing to sustain competitive advantage in the anti-amyloid arena. Several sponsors have emphasized diversified pipelines that include next-generation monoclonal antibodies with optimized Fc engineering, small molecules targeting aggregation pathways, and vaccine platforms designed for durable immune responses. Strategic partnerships and licensing arrangements have accelerated scale-up of manufacturing capacity, enabled rapid access to specialized formulation expertise, and facilitated co-development models that share regulatory and commercial risk.

In parallel, companies are investing in companion diagnostics and biomarker partnerships to support patient selection, treatment monitoring, and post-market evidence generation. Commercial organizations are piloting innovative service offerings-including home infusion models, patient navigation programs, and digital therapeutics adjuncts-to improve adherence and clinical outcomes. Mergers and targeted acquisitions continue to serve as levers to secure talent, platform technologies, and regional market entry. Collectively, these company-level strategies highlight a shift from single-product focus toward integrated therapeutic ecosystems that combine scientific innovation with pragmatic delivery solutions to maximize clinical benefit and patient access.

Targeted and pragmatic recommendations for companies to align diagnostics, manufacturing resilience, site-of-care strategies, and payer engagement to optimize launches and access

Industry leaders should prioritize a concise set of actionable moves that align clinical objectives with commercial and operational realities. First, integrate diagnostic and therapeutic pathways by forging collaborations with biomarker providers and payers to enable timely patient identification and outcomes tracking. Doing so will reduce friction in patient journeys and strengthen coverage arguments with real-world evidence. Second, invest in flexible manufacturing and supply chain redundancy by expanding geographically diversified capacity and adopting modular fill-finish solutions to protect against tariff and logistics disruptions.

Third, design differentiated access models that account for site-of-care preferences, shifting portions of care to outpatient infusion and home administration where clinically appropriate, while ensuring robust clinical support and training. Fourth, embed outcomes-based contracting pilots within early launch plans to demonstrate value alignment with payers and health systems, and to generate the longitudinal data required for broader reimbursement acceptance. Finally, cultivate multi-stakeholder engagement strategies that include patient advocacy groups, specialist clinicians, and health technology assessment bodies to build consensus around clinical benefit thresholds and acceptable safety profiles. By executing these measures in parallel, organizations can de-risk launches, accelerate uptake, and secure sustainable pathways to patient access.

A transparent and robust research methodology combining expert interviews, regulatory and clinical evidence synthesis, and scenario-driven analytical techniques to support strategic decision-making

This analysis synthesizes primary and secondary research methodologies to produce a rigorous, multidimensional view of the anti-amyloid therapeutic ecosystem. Primary inputs include structured interviews with clinical experts, payers, and manufacturing leaders, as well as consultations with regulatory affairs specialists and diagnostic providers to ground assumptions in operational realities. These qualitative insights were triangulated with publicly available regulatory filings, peer-reviewed literature, clinical trial registries, and corporate disclosures to verify clinical outcomes, safety signals, and strategic positioning.

Analytical approaches included cross-functional scenario planning to assess implications of delivery format choices and tariff-induced supply disruptions, and segmentation overlays to elucidate patient journey bottlenecks across indication, route of administration, and end-user settings. Regional analysis drew on regulatory decision histories and health system architectures to interpret access dynamics. Throughout, findings emphasize transparency in data provenance and limitations, and recommendations were stress-tested against alternative regulatory and commercial scenarios to ensure robustness for decision-makers.

Synthesis of clinical momentum, operational imperatives, and strategic priorities that leaders must address to translate scientific advances into durable patient access and commercial success

In conclusion, the anti-amyloid therapeutics landscape presents a rare combination of scientific progress and systemic complexity that requires integrated, anticipatory strategies. Clinical advances have created credible therapeutic options, but their commercial success depends on coordinated investments in diagnostics, manufacturing agility, payer engagement, and patient-centric delivery models. Policy developments, including tariff changes and evolving reimbursement paradigms, elevate the importance of supply chain diversification and contractual flexibility.

Looking ahead, organizations that translate scientific innovation into reliable, accessible care pathways will distinguish themselves. This will demand cross-functional alignment across R&D, regulatory, commercial, and operations teams, along with proactive stakeholder engagement and data-driven access strategies. By focusing on resilient manufacturing, evidence-generation that aligns with payer priorities, and adaptable distribution models, leaders can convert current momentum into tangible patient impact and sustainable organizational value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-amyloid Drugs Market, by Drug Type

  • 8.1. Monoclonal Antibodies
    • 8.1.1. Chimeric
    • 8.1.2. Fully Human
    • 8.1.3. Humanized
    • 8.1.4. Murine
  • 8.2. Peptide-Based Therapies
  • 8.3. Small Molecule Inhibitors
    • 8.3.1. Aggregation Inhibitors
    • 8.3.2. Secretase Inhibitors
  • 8.4. Vaccines
    • 8.4.1. DNA Vaccines
    • 8.4.2. Peptide Vaccines

9. Anti-amyloid Drugs Market, by Indication

  • 9.1. Alzheimer's Disease
  • 9.2. Huntington's Disease
  • 9.3. Multiple Sclerosis
  • 9.4. Parkinson's Disease

10. Anti-amyloid Drugs Market, by Route Of Administration

  • 10.1. Intrathecal
  • 10.2. Intravenous
    • 10.2.1. Inpatient Infusion
    • 10.2.2. Outpatient Infusion
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Liquid
    • 10.3.3. Tablet
  • 10.4. Subcutaneous

11. Anti-amyloid Drugs Market, by Patient Stage

  • 11.1. Early Stage
  • 11.2. Late Stage
  • 11.3. Mid Stage

12. Anti-amyloid Drugs Market, by End User

  • 12.1. Home Care Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Anti-amyloid Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Anti-amyloid Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Anti-amyloid Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Anti-amyloid Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Anti-amyloid Drugs Market

18. China Anti-amyloid Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Biogen Inc.
  • 19.9. Bristol Myers Squibb Company
  • 19.10. Eisai Co. Ltd.
  • 19.11. Eli Lilly and Company
  • 19.12. Johnson & Johnson
  • 19.13. Merck & Co. Inc.
  • 19.14. Novartis AG
  • 19.15. Pfizer Inc.
  • 19.16. Roche Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-AMYLOID DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-AMYLOID DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY AGGREGATION INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY AGGREGATION INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY AGGREGATION INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SECRETASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SECRETASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SECRETASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INPATIENT INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INPATIENT INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INPATIENT INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY OUTPATIENT INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY OUTPATIENT INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY OUTPATIENT INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LATE STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LATE STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LATE STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MID STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MID STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MID STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 228. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 230. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 264. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 266. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 269. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 270. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. G7 ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 276. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 278. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 279. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. NATO ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)